143 articles
Depemokimab
Depemokimab (trade name Exdensur) is a GSK monoclonal antibody that blocks interleukin-5, given twice yearly for severe eosinophilic asthma and chronic rhinosinusitis with nasal polyps.
Dirucotide
Dirucotide (MBP8298), a 17-amino-acid myelin basic protein peptide, was an intravenous antigen-specific tolerance therapy for HLA-DR2/DR4 secondary progressive MS, discontinued in 2009 after the Phase III MAESTRO-01 trial missed its EDSS progression endpoint.
Ebdarokimab
Ebdarokimab (AK101, Aidaro, 依若奇单抗) is a human IgG1κ monoclonal antibody by Akeso binding the IL-12/IL-23 p40 subunit; approved in China April 2025 for moderate-to-severe plaque psoriasis, 135 mg SC, PASI 75 79.4% at week 16.
Ebronucimab (AK102)
Ebronucimab (伊努西单抗, AK102, brand 伊喜宁) is a fully human IgG1 anti-PCSK9 monoclonal antibody by Akeso/AD Pharmaceuticals, approved in China on 26 September 2024 for primary hypercholesterolemia and mixed dyslipidemia, dosed 150 mg Q2W or 450 mg Q4W.
Edobacomab
Edobacomab (E5, Xomen E5, XMMEN-0E5) is a murine IgM monoclonal antibody against gram-negative bacterial endotoxin (lipid A), developed by XOMA for sepsis; its phase III trials showed no survival benefit.
Efalizumab
Efalizumab (Raptiva, anti-CD11a) was a humanized IgG1 monoclonal antibody for plaque psoriasis, FDA-approved 2003 and EU-authorized 2004, withdrawn from both markets in 2009 over progressive multifocal leukoencephalopathy risk.
Efgartigimod alfa
Efgartigimod alfa, sold by argenx as VYVGART, is a neonatal Fc receptor blocker that lowers circulating IgG; the FDA approved it in 2021 for generalized myasthenia gravis.
Elranatamab
Elranatamab, sold as Elrexfio, is a humanized bispecific antibody developed by Pfizer that binds BCMA on myeloma cells and CD3 on T cells, approved in 2023 for relapsed multiple myeloma.
Envafolimab
Envafolimab (ENWEIDA, 恩维达, KN035) is a subcutaneously injectable humanized single-domain anti-PD-L1 antibody fused to human IgG1 Fc, approved in China in November 2021 for previously treated MSI-H/dMMR advanced solid tumors.
Eplontersen
Eplontersen (Wainua, Wainzua) is a GalNAc-conjugated antisense oligonucleotide silencing liver TTR mRNA, FDA-approved December 2023 at 45 mg monthly subcutaneously for hereditary transthyretin amyloidosis polyneuropathy; its ATTR-CM trial failed.
Epratuzumab
Epratuzumab (AMG 412, hLL2, LymphoCide) is a humanized anti-CD22 IgG1 monoclonal antibody with partial B-cell depletion, tested in SLE through phase III EMBODY trials, which failed, leaving it unapproved.
Etuvetidigene autotemcel
Etuvetidigene autotemcel (Waskyra, etu-cel) is an autologous lentiviral HSPC gene therapy for Wiskott-Aldrich syndrome, approved by FDA December 9, 2025 and EMA January 9, 2026, marketed by Fondazione Telethon.
Evinacumab
Evinacumab (Evkeeza), an ANGPTL3-inhibiting IgG4 monoclonal antibody by Regeneron, FDA-approved February 2021, lowers LDL-C via an LDL receptor-independent mechanism in homozygous familial hypercholesterolemia.
Expanded Activated Lymphocytes (EAL)
Expanded Activated Lymphocytes (EAL, 扩增活化的淋巴细胞, 爱可仑赛注射液) is Beijing Yongtai's autologous non-gene-modified CIK-type T-cell immunotherapy for preventing hepatocellular carcinoma recurrence after resection; CDE breakthrough therapy 2023, conditional marketing application accepted 2025.
Farletuzumab
Farletuzumab (MORAb-003) is a humanized IgG1 monoclonal antibody against folate receptor alpha for ovarian cancer; its phase III trials missed PFS endpoints, and it now anchors the ADC farletuzumab ecteribulin (MORAb-202).
Felzartamab
Felzartamab (MOR202, TJ202) is a fully human anti-CD38 IgG1 monoclonal antibody by Biogen that depletes plasma cells and NK cells; in phase 2 trials it resolved antibody-mediated kidney-transplant rejection and reduced proteinuria in membranous nephropathy and IgA nephropathy.
Forigerimod
Forigerimod (P140, Lupuzor, IPP-201101) is a 21-mer phosphopeptide from U1-70K snRNP that binds HSC70/HSPA8 to treat lupus; Phase IIb positive, Phase III missed its endpoint, CIDP in development.
Givosiran
Givosiran (Givlaari) is a GalNAc-conjugated siRNA degrading liver ALAS1 mRNA, given 2.5 mg/kg monthly subcutaneously for acute hepatic porphyria; approved US 2019, EU 2020, cutting attacks by 74%.
GNX201 (ADC)
GNX201-ADC is GlycoNex's preclinical pro-antibody antibody-drug conjugate for solid tumors, using PrecisemAb AntibodyLock masking and a tumor-associated carbohydrate antigen target, co-developed with Nippon Kayaku since March 2026.
Goflikicept
Goflikicept (RPH-104), an R-Pharm IL-1α/IL-1β trap fusion protein with a 10-day half-life, dosed subcutaneously every 2 weeks; in a phase II/III trial for idiopathic recurrent pericarditis it gave 0% recurrences versus 90% on placebo.
Guselkumab
Guselkumab (Tremfya) is a fully human IgG1λ monoclonal antibody blocking the IL-23 p19 subunit, developed by Johnson & Johnson. First approved 2017 for plaque psoriasis; later indications include psoriatic arthritis, ulcerative colitis, Crohn's disease, and, from 2025, pediatric psoriasis and psoriatic arthritis.
Harbour BioMed BCMA×CD3 bispecific T-cell engager (licensed to Otsuka)
HBM7020, a BCMA×CD3 bispecific T-cell engager from Harbour BioMed's HBICE/Harbour Mice platforms, uses a 2+1 format to deplete BCMA-positive B cells; NMPA IND cleared 2023, licensed ex-Greater China to Otsuka in June 2025 for autoimmune disease.
HEMACORD
Hemacord (HPC, Cord Blood) is the first FDA-licensed cord blood hematopoietic progenitor cell therapy (BLA 125397, New York Blood Center, approved November 10, 2011) for unrelated donor transplantation for hematopoietic and immunologic reconstitution.
Henlius rituximab biosimilar (HLX01, Hanlikang)
HLX01, sold in China as Hanlikang (汉利康), is a rituximab biosimilar developed by Shanghai Henlius Biotech and approved in 2019 as the first biosimilar approved in China.
Ianalumab
Ianalumab (VAY736) is Novartis's fully human anti-BAFF-R IgG1 monoclonal antibody combining B-cell depletion via ADCC with BAFF-R blockade, developed for Sjögren's disease, ITP, SLE, and wAIHA; its NEPTUNUS Phase III trials were the first in Sjögren's to meet an ESSDAI endpoint.
Idarucizumab
Idarucizumab (Praxbind) is a humanized monoclonal antibody fragment by Boehringer Ingelheim that reverses dabigatran anticoagulation; US approval October 2015, 5 g IV dose, rebound risk in renal impairment.
Idecabtagene vicleucel
Idecabtagene vicleucel (ide-cel, BB2121, Abecma) is an autologous anti-BCMA CAR T-cell therapy for relapsed/refractory multiple myeloma; FDA approved March 2021, KarMMa ORR 73%.
Ifinatamab deruxtecan
Ifinatamab deruxtecan (I-DXd, DS-7300) is a B7-H3-directed antibody-drug conjugate with a DXd topoisomerase I inhibitor payload, DAR 4, developed by Daiichi Sankyo and Merck for SCLC, prostate, and esophageal cancers; FDA priority review 2026.
Imsidolimab
Imsidolimab (ANB019) is a humanized IgG4 monoclonal antibody antagonist of the interleukin-36 receptor developed by AnaptysBio and licensed to Vanda Pharmaceuticals, tested in phase 2 GALLOP and phase 3 GEMINI-1/2 trials for generalized pustular psoriasis, with a US BLA under review.
Ixekizumab
Ixekizumab (Taltz), Eli Lilly's humanized IgG4 monoclonal antibody against interleukin-17A, injected subcutaneously for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondyloarthritis; first FDA-approved March 22, 2016.